Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Active not recruiting 11Recruiting 10Completed 8Terminated 5Not yet recruiting 4Withdrawn 3Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × tafasitamab × Lymphoid × Clear all
NCT04809467 2026-02-04

topMIND

Incyte Corporation

Phase 1/2 Terminated
54 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Pfizer

Phase 1/2 Terminated
6 enrolled 17 charts
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05788289 2025-05-25

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 8 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Xencor, Inc.

Phase 2 Terminated
3 enrolled 6 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT01685021 2018-02-22

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

MorphoSys AG

Phase 2 Terminated
22 enrolled 12 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡